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 ABSTRACT
Objective: To determine prevalence of thyroid antimicrosomal and antithyroglobulin 
antibodies among patients with primary thyroid disorders.
Design: Descriptive cross-sectional study.
Setting: Kenyatta National Hospital, July 2003 to August 2004.
Results: Antimicrosomal antibodies (anti-TPOAbs) were detected in 51.4% of all the 
patients while 36.1% tested positive for the antithyroglobulin antibodies (anti- TgAbs). 
Among the hyperthyroid patients, anti-TPOAbs and anti-TgAbs were in 50.8% and 
33% respectively while 53.3% and 46.7% of the hypothyroid patients tested positive for 
anti-TPOAbs and anti-TgAbs respectively. Most of the patients who showed positivity 
for anti-TgAbs (88.5%) also tested positive for anti-TPOAbs. 
Conclusion: More than half of the patients with primary thyroid disorders show presence 
of autoimmune thyroid markers, with anti TPO antibodies being more prevalent. 
INTRODUCTION 
The role of autoantibodies in the causation of 
functional thyroid disorders has been known 
for a long time (1). Autoimmune thyroiditis was 
first described by Hashimoto who reported four 
patients with goitre in whom the thyroid histological 
appearance manifested among other features diffuse 
lymphocytic infiltration (2). In areas where there 
is no iodine deficiency, autoimmunity has become 
the commonest cause of thyroid disease (1). The 
two main antibodies implicated in autoimmune 
thyroid disease are antithyroperoxidase and 
antithyroglobulin antibodies. These autoantibodies 
can exert a stimulating or a blocking effect on cell 
membrane receptors leading to alteration in thyroid 
gland function.
 The reported prevalence of  thyroid 
autoantibodies shows variability depending on 
the geographical location, gender, age as well as 
the sensitivity and specificity of the analytical 
methodology used to determine the autoantibodies. 
Higher prevalence rates have been reported when 
sensitive methods for autoantibodies detection are 
utilised.
 A large study in the United States involving more 
than 17,000 subjects found anti-TPOAbs and anti-
TgAbs, in 11.3% and 10.4% of euthyroid individuals 
respectively (3). Most of the patients with thyroid 
disease had detectable antithyroid antibodies. In 
another study, anti-TPOAbs and anti-TgAbs were 
found to be present in 85% and 30% to 60 % of patients 
with primary thyroid diseases respectively (4). 
 Reports on antithyroid antibodies among 
Africans are few and mostly emanate from studies 
using agglutination methods which have low 
sensitivity and specificity. An earlier local study 
reported anti-TPOAbs and anti-TgAbs in 54% and 12% 
of patients with thyrotoxicosis respectively (5). More 
recently, Okosieme et al, (6) using a sensitive ELISA 
technique, reported presence of anti-TgAbs and anti-
TPOAbs in 11.6% and 76.8% of Nigerian patients with 
Graves disease. This study sought to determine the 
prevalence of these thyroid antibodies among patients 
with primary hyper- and hypothyroidism, using the 
more sensitive assays that have been developed. 
MATERIALS AND METHODS 
This was a descriptive cross-sectional study carried 
out at the Kenyatta National Hospital, Nairobi. 
Between July 2003 and August 2004 serum samples 
from patients aged 15 to 60 years with primary 
hyperthyroidism and hypothyroidism were tested 
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for the presence of anti-TPOAbs and anti-TgAbs. 
Approval for the study was obtained from the 
KNH-Ethical Research Committee (KNH-ERC) 
and all patients gave informed consent. Patients 
with secondary causes of thyroid dysfunction such 
as pituitary disease and pregnant women were 
excluded from the study. Determination of anti-
thyroid antibodies was done using an ELISA method 
with commercial reagents. Results were reported in 
index values. Index values > 1.10 were considered 
positive. 
 RESULTS
Out of the 72 subjects with primary thyroid disease, 
57 had hyperthyroidism and 15 had hypothyroidism. 
Most of the patients (80.6%) were females and majority 
(70.8%) were in the 31-50 years age group. Anti-
TPOAbs and anti-TgAbs antibodies were detected 
in 51.3% and 36.1% of the patients respectively 
(Figure 1). 
Figure 1
Age related distribution of anti -TgAbs seropositivity
 
Table 1
Seropositivity to antithyroid antibodies in patients with primary thyroid  disorders 
   Anti- TgAbs Anti-TPOAbs Positive for Negative for
  Positive Positive   both Abs  both Abs
  No.  (%) No.  (%) No.  (%) No.  (%)
Hyperthyroid  Males   6  23.1  6   16.2   5    21.7  3   9.4
 Females 13  50  23   62.2  12   52.2  23   71.9
Hypothyroid Males  2   7.7  2   5.4  2   8.7  2   6.2
 Females  5  19.2  6   16.2   4   17.4  4    12.5
  Total  26  100  37   100  23   100  32   100
 
 Figure 2
Age related distribution of anti-TPOAbs seropositivity 
 
Twenty nine (50%) of the female patients tested 
positive for anti-TPOAbs while 18 (31%) of the females 
tested positive for anti-TgAbs. Eight males tested 
positive for each of the antibodies (Table 1). Most 
of the patients who were positive for anti-TPOAbs 
(88.5%) were also positive for anti-TgAbs. Among the 
patients who tested positive for the antibodies, levels 
of anti-TPOAbs ranged from 21 to 688 IU while those 




Autoimmune thyroid diseases are among the most 
common autoimmune disorders in man. It has been 
reported that thyroid autoimmunity is rare in iodine 
deficient areas but becomes more prevalent with 
improvement in iodine nutrition (6-8). Locally, it is a 
requirement that all domestic salt is iodinated in an 
attempt to reduce the occurrence of iodine deficiency 
disorders (9). The presence of antimicrosomal 
antibodies (anti-TPOAbs) is the hallmark of disease 
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activity (10). It is generally known that females 
suffer more from autoimmune thyroid disorders 
than males (11). In this study, 80.6% patients were 
females. This compares with the study from Nigeria 
which found 77.9% of patients with thyroid disorders 
being females (6).
 Fifty seven per-cent of the males and 50% 
of the female patients studied tested positive for 
anti-TPOAbs. This is similar to a report from Asia 
where 59% of the male and 51.67% of the female 
patients studied tested positive for the antibody 
(12). As in this study, most of the patients in the 
study were in the 30 to 50 year age group. In a recent 
study among 104 patients with thyroid disorders 
in Nigeria, anti-TPOAbs were found in 60.5% of 
the patients (6). 
 Among the hyperthyroid patients in this study, 
51.3% tested positive for anti-TPOAbs. This compares 
with the 54% found to have the antibodies in an earlier 
study done locally using haemagglutination method 
(5). In contrast, 36.1% of the hyperthyroid patients 
showed positivity to anti-TgAbs which is higher than 
what had been reported in previous studies done 
locally (5,13). 
 The difference in the positivity rate for anti-
TgAbs between these studies is likely to be a reflection 
of the differences in sensitivities of the methods used. 
Indirect immunofluorescence and haemagglutination 
methods, both of which are less sensitive than the 
ELISA method used in the current study were used 
in the previous studies. It may also reflect an increase 
in the immunological burden due to the high level 
of environmental pollution and many parasitic and 
infectious diseases leading to increased production 
of autoantibodies to various body tissues including 
the thyroid (14). 
 Previous reports indicate that anti-TgAbs 
occur more frequently in females than in males (3). 
A higher proportion of hyperthyroid males (60%) 
showed positivity for the antibody than hyperthyroid 
females (27.6%) in the current study. However, the 
number of hyperthyroid males in this study was small 
(n=10), and may therefore not be representative of 
the population. Among the hypothyroid patients, 
antithyroid antibodies were detected in 53.3%. These 
were mainly anti-TPOAbs with only a few cases 
showing reactivity to anti-TgAbs alone. 
 Most of the patients (88.5%) who tested positive 
for anti-TPOAbs were also positive for the anti-
TgAbs antibodies. On the other hand, only 62.7% 
of those who were positive for anti-TPOAbs tested 
positive for anti-TgAbs. This finding is similar to 
what is reported in the literature where up to 100% 
of patients with anti-TgAbs tested positive for 
anti-TPOAbs (1,4). This may be because the two 
antibodies are polyclonal (15). Again, the number 
of epitopes in the anti-TgAbs is large as seen in 
some of the antisera raised from hyperimmunised 
animals showing up to 40 epitopes (16), and the two 
antigens have been shown to share some common 
epitopes (17).
 It is also known that when these two antibodies 
are present, the anti-TPOAbs titres are usually higher 
(1,5). In this study, the mean titres of anti-TPOAbs 
were higher than those of anti-TgAbs. Also, patients 
who tested positive for both antibodies tended to 
have higher titres of anti-TPOAbs than of anti-TgAbs. 
In resource poor settings, it may therefore be cost 
effective to only measure the levels of anti-TPOAbs as 
a surrogate marker for autoimmunity. No association 
was however found between the titres of anti-TgAbs 
or anti-TPOAbs and the severity of thyroid hormone 
disturbance. This is similar to what was reported in 
an earlier study (3).
 Studies done using modern assay techniques 
have shown that anti-TPOAbs develop in almost 
all patients with autoimmune thyroid disease 
during some stage in the disease process (10). Anti-
TPOAbs are now considered as a more important 
marker for autoimmune thyroid disease than 
anti-TgAbs (12,18). In thyrotoxic patients with 
autoimmune thyroid disease, titres of anti-TPOAbs 
tend to fall once they become euthyroid (19). This 
also happens among hypothyroid patients who 
are treated with thyroxine. It has been shown 
that patients with Grave’s disease who have high 
titres of anti-TgAbs and/or anti-TPOAbs are more 
likely to become hypothyroid later (20). Medical 
treatment is the mainstay of treatment of patients 
with Grave’s disease but surgery is indicated in 
patients with large symptomatic goiters and those 
intolerant to antithyroid medication. Surgery is also 
recommended in those with failure to respond to 
antithyroid drugs and those with nodules which 
are suspicious for malignancy (21). A follow up 
study done in England among  163 asymptomatic 
patients with elevated levels of TSH who were also 
positive for thyroid antibodies (anti-TPO, anti-
TgAbs) showed that these patients developed overt 
hypothyroidism at the rate of 5% per annum (22). 
 Markers of autoimmune thyroid disease are 
prevalent among Kenyan patients with primary 
thyroid disorders and the positivity of anti-TgAbs is 
higher than earlier reported. This study was however 
limited by the small sample size, and it did not 
include healthy subjects. The specificity of the thyroid 
autoimmune markers was therefore not evaluated. 
Validation of these findings is needed using a wider 
study, including both healthy individuals and patients 
with thyroid disorders. 
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